Belumosudil for Chronic Graft-Versus-Host Disease: A Systematic Review and Meta-Analysis
Belumosudil demonstrates promising efficacy and a favorable safety profile in refractory cGvHD. Our findings support further investigation in earlier treatment and disease course.
Authors
- Ina Rudolph
- Kristin Rathje
- Radwan Massoud (ORCID: https://orcid.org/0000-0001-9275-3840)
- Catherina Lueck (ORCID: https://orcid.org/0000-0001-9597-6142)
- Johanna Richter (ORCID: https://orcid.org/0000-0002-2043-0003)
- Nico Gagelmann (ORCID: https://orcid.org/0000-0002-0891-1744)
- Silke Heidenreich
- Franziska E. Marquard
- Francis Ayuk (ORCID: https://orcid.org/0000-0001-6297-1847)
- Evgeny Klyuchnikov (ORCID: https://orcid.org/0000-0001-9407-1413)
Institutions
- Universität Hamburg (DE)
- University Medical Center Hamburg-Eppendorf (DE)
Publication Details
- Journal
- Transplantation and Cellular Therapy
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1016/j.jtct.2025.11.019
- Citations
- 1
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.77